表紙
市場調查報告書

橫紋肌肉瘤:開發中產品分析

Rhabdomyosarcoma - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 245966
出版日期 內容資訊 英文 418 Pages
訂單完成後即時交付
價格
Back to Top
橫紋肌肉瘤:開發中產品分析 Rhabdomyosarcoma - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 418 Pages
簡介

橫紋肌肉瘤(RMS),是從正常的骨骼肌肉細胞派生的惡性腫瘤(癌症)。為何正常的骨骼肌肉細胞患癌症,大部分什麼都沒闡明。骨骼肌肉細胞幾乎存在人體所有地方,橫紋肌肉瘤在人體的任何部分都可能發病。

本報告提供全球各國的橫紋肌肉瘤治療用的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將其結果為您概述為以下內容。

簡介

  • 分析範圍

橫紋肌肉瘤概要

治療藥的開發

  • 橫紋肌肉瘤的開發中產品:概要
  • 橫紋肌肉瘤的開發中產品:各企業
  • 橫紋肌肉瘤的開發中產品:各大學/研究機關
  • 橫紋肌肉瘤治療藥:開發中的產品一覽(各企業)
  • 橫紋肌肉瘤治療藥:各研究中的產品一覽(大學/研究機關)

橫紋肌肉瘤:治療藥的評估

  • 各標的
  • 各行動機制
  • 各投藥法
  • 各分子類型

橫紋肌肉瘤開發治療藥的企業

  • Bellicum Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corporation
  • Eisai
  • EpiZyme, Inc.
  • Exelixis Inc.
  • Iproteos SL
  • Ipsen SA
  • MacroGenics Inc.
  • NantKwest Inc.
  • Novartis AG
  • Noxxon Pharma AG
  • Pfizer Inc.
  • 大鵬藥品工業
  • Taiwan Liposome Company Ltd
  • Tarveda Therapeutics Inc

藥物簡介

橫紋肌肉瘤治療藥:開發暫停的產品

橫紋肌肉瘤治療藥:開發中止的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11726IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2019, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 20, 9, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 2 molecules, respectively.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rhabdomyosarcoma - Overview
    • Rhabdomyosarcoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Rhabdomyosarcoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rhabdomyosarcoma - Companies Involved in Therapeutics Development
    • Advenchen Laboratories LLC
    • Alxerion Biotech Corp
    • Amgen Inc
    • Arisaph Pharmaceuticals Inc
    • Bayer AG
    • Biogenera SpA
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Co
    • Cellectar Biosciences Inc
    • Cellestia Biotech AG
    • Eisai Co Ltd
    • Epizyme Inc
    • Exelixis Inc
    • F. Hoffmann-La Roche Ltd
    • Galapagos NV
    • ImmunityBio Inc
    • Iproteos SL
    • Ipsen SA
    • MacroGenics Inc
    • Mana Therapeutics Inc
    • NanoRED Biotechnology
    • NantKwest Inc
    • Novartis AG
    • Oncoheroes Biosciences Inc
    • Oncolys BioPharma Inc
    • Oxurion NV
    • Pfizer Inc
    • Provectus Biopharmaceuticals Inc
    • Seneca Therapeutics Inc
    • Shionogi & Co Ltd
    • Sorrento Therapeutics Inc
    • Taiho Pharmaceutical Co Ltd
    • Taiwan Liposome Co Ltd
    • Tarveda Therapeutics Inc
    • Veana Therapeutics LLC
    • Zenyaku Kogyo Co Ltd
  • Rhabdomyosarcoma - Drug Profiles
  • Rhabdomyosarcoma - Dormant Projects
  • Rhabdomyosarcoma - Discontinued Products
  • Rhabdomyosarcoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Rhabdomyosarcoma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Rhabdomyosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2019
  • Rhabdomyosarcoma - Pipeline by Alxerion Biotech Corp, H2 2019
  • Rhabdomyosarcoma - Pipeline by Amgen Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Bayer AG, H2 2019
  • Rhabdomyosarcoma - Pipeline by Biogenera SpA, H2 2019
  • Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Rhabdomyosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Rhabdomyosarcoma - Pipeline by Cellectar Biosciences Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Cellestia Biotech AG, H2 2019
  • Rhabdomyosarcoma - Pipeline by Eisai Co Ltd, H2 2019
  • Rhabdomyosarcoma - Pipeline by Epizyme Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Exelixis Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Rhabdomyosarcoma - Pipeline by Galapagos NV, H2 2019
  • Rhabdomyosarcoma - Pipeline by ImmunityBio Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Iproteos SL, H2 2019
  • Rhabdomyosarcoma - Pipeline by Ipsen SA, H2 2019
  • Rhabdomyosarcoma - Pipeline by MacroGenics Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Mana Therapeutics Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by NanoRED Biotechnology, H2 2019
  • Rhabdomyosarcoma - Pipeline by NantKwest Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2019
  • Rhabdomyosarcoma - Pipeline by Oncoheroes Biosciences Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Oxurion NV, H2 2019
  • Rhabdomyosarcoma - Pipeline by Pfizer Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Seneca Therapeutics Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Shionogi & Co Ltd, H2 2019
  • Rhabdomyosarcoma - Pipeline by Sorrento Therapeutics Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
  • Rhabdomyosarcoma - Pipeline by Taiwan Liposome Co Ltd, H2 2019
  • Rhabdomyosarcoma - Pipeline by Tarveda Therapeutics Inc, H2 2019
  • Rhabdomyosarcoma - Pipeline by Veana Therapeutics LLC, H2 2019
  • Rhabdomyosarcoma - Pipeline by Zenyaku Kogyo Co Ltd, H2 2019
  • Rhabdomyosarcoma - Dormant Projects, H2 2019
  • Rhabdomyosarcoma - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Rhabdomyosarcoma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top